GIP and GLP-1 receptor co-agonist
BGM0504 15 mg injection once weekly
BGM050_SC_15MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.72 (0.01 to 59.18) | 0.53 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.37 (0.00 to 13.17) | 0.66 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.54 (0.01 to 22.23) | 0.67 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 23.28 (6.33 to 107) | 0.01 |